Immunosuppressive treatment of rheumatic diseases during pregnancy

  • Monika Østensen


Rheumatic diseases have a predilection for the female sex and often become manifest during womens, childbearing years. The interaction of pregnancy and rheumatic diseases varies, some conditions benefit, others worsen in response to the immunological and hormonal alterations of pregnancy. Diseases which remain active during pregnancy may need drug treatment either for the benefit of the mother or in order to protect pregnancy and the fetus. Most often, immunosuppressive treatment is required in disorders associated with involvement of internal organs and autoimmune phenomena (Table 1).


Systemic Lupus Erythematosus Rheumatic Disease Mycophenolate Mofetil Oral Cleft Tumor Necrosis Factor Alpha Inhibition 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Alstead EM, Ritchie JK, Lennard-Jones JE, Farthing MJG, Clark ML (1990) Safety of azathioprine in pregnancy in inflammatory bowel disease. Gastroenterology 99: 443–446PubMedGoogle Scholar
  2. Armenti VT, Ahlswede KM, Ahlswede BA, Jarrell BE, Moritz MJ, Burke JF (1994) National transplantation pregnancy registry: outcomes of 154 pregnancies in cyclosporine-treated female kidney transplant recipients. Transplantation 57: 502–506PubMedGoogle Scholar
  3. Armenti VT, Moritz MJ, Davison JM (1998) Drug safety issues in pregnancy following transplantation and immunosuppression. Drug Saf 19: 219–232PubMedCrossRefGoogle Scholar
  4. Branch DW, Peaceman AM, Druzin M et al. (2000) A multicenter, placebo-controlled pilot study of intravenous immune globuline treatment of antiphospholipid syndrome during pregnancy. Am J Obstet Gynecol 182: 122–127PubMedCrossRefGoogle Scholar
  5. Briggs GG, Freeman RK, Yaffe SJ (1998) Drugs in pregnancy and lactation, 5th edn. Williams & Wilkins. Baltimore, pp 272c-279cGoogle Scholar
  6. Brent RL (1998) Leflunomide as an example of a modern approach to product labelling for reproductive effects: a category X drug based on pharmacokinetic data. Teratology 58: 445Google Scholar
  7. Brent RL (2001) Teratogen update: reproductive risks of leflunomide (Arava), a pyrimidine synthesis inhibitor: counseling women taking leflunomide before or during pregnancy and men taking leflunomide who are contemplating fathering a child. Teratology 63: 106–112PubMedCrossRefGoogle Scholar
  8. Buchanan NMM, Toubi E, Khamashta KE, Lima F, Kerslake S, Hughes GRV (1996) Hy doxy chloroquine and lupus pregnancy: review of a series of 36 cases. Ann Rheum Dis 55: 486–488PubMedCrossRefGoogle Scholar
  9. Cockburn I, Krupp P, Monka C (1989) Present experience of Sandimmun in pregnancy. Transplant Proc 21: 3730–3732PubMedGoogle Scholar
  10. Coté CJ, Meuwissen HG, Pickering RJ (1974) Effects on the neonate of prednisone and azathioprine administered to the mother during pregnancy. J Pediatr 85: 324–328PubMedCrossRefGoogle Scholar
  11. Davison JM, Dellagrammatikos H, Parkin JM (1985) Maternal azathioprine therapy and depressed haemopoiesis in the babies of renal allograft patients. Br J Obst Gynecol 92: 233–239CrossRefGoogle Scholar
  12. Di Paolo S, Schena A, Morrone LF, Manfredi G, Stallone G, Derosa C, Procino A, Schena FP (2000). Immunologic evaluation during the first year of life of infants born to cyclosporine-treated female kidney transplant recipients. Transplantation 69: 2049–2054PubMedCrossRefGoogle Scholar
  13. Doll CD, Ringenberg QS, Yarbro JW (1989) Antineoplastic agents and pregnancy. Semin Oncol 16: 337–346PubMedGoogle Scholar
  14. Fraser FC, Sajoo A (1985) Teratogenic potential of corticosteroids in humans. Teratology 51: 4546Google Scholar
  15. Gaughan WJ, Moritz MJ, Radomski JS, Burke JF Jr, Armenti VT (1996) National Transplantation Pregnancy Registry: report on outcomes in cyclosporine-treated female kidney transplant recipients with an interval from transplant to pregnancy of greater than five years. Am J Kidney Dis 28: 266–269PubMedCrossRefGoogle Scholar
  16. Goroir BP, Peppel K, Silva M, Beutler B (1992) The biosynthesis of tumor necrosis factor during pregnancy: studies with a CAT reporter transgene and TNF inhibitors. Eur Cytokine Network 3: 533–537Google Scholar
  17. Harris EN, Pierangeli SS (1998) Utilization of intravenous immunoglobulin therapy to treat recurrent pregnancy loss in the antiphospholipid syndrome: a review. Scand J Rheumatol (Suppl) 107: 97–102Google Scholar
  18. Hart CN, Naunton RF (1964) The ototoxicity of chloroquine phosphate. Arch Otolaryngol Head Neck Surg 80: 407–412CrossRefGoogle Scholar
  19. Hernandez-Diaz S, Werler MM, Walker AM, Mitchell AA (2000) Folic acid antagonists during pregnancy and the risk of birth defects. N Eng J Med 343: 1608–1614CrossRefGoogle Scholar
  20. Katz JA, Lichtenstein GR, Keenan GF, Healy DE, Jacobs SJ (2001) Outcome of pregnancy in women receiving remicade (Infliximab) for the treatment of Crohn’s disease or rheumatoid arthritis. American Gastroenterological Association, Digestive Disease Week, Atlanta, April 2001, Abstract 366Google Scholar
  21. Kozlowska-Boszko B, Soluch L, Rybus J, Lao M, Durlik M, Gaciong Z (1996) Does chronic glucosteroid therapy in pregnant renal allograft recipients affect Cortisol levels in neonates? Transplant Proc 28: 3490–3491PubMedGoogle Scholar
  22. Kraus AM (1975) Congenital cataract and maternal steroid injection. J Pediatr Ophthalmol Strabismus 12: 107–108Google Scholar
  23. Lamarque V, Leleu MF, Monka C, Krupp P (1997) Analysis of 629 pregnancy outcomes in transplant recipients treated with Sandimmun. Transplant Proc 29: 2480PubMedCrossRefGoogle Scholar
  24. Le Thi Huong D, Wechsler B, Bletry O, Vauthier-Brouzes D, Lefebvre G, Piette JC (2001) A study of 75 pregnancies in patients with antiphospholipid syndrome. J Rheumatol 28: 2025–2030Google Scholar
  25. Levi S, Liberman M, Levi AJ, Bjarnason I (1988) Reversible congenital neutropenia associated with maternal sulphasalazine therapy (letter). Eur J Pediatr 148: 174–175PubMedCrossRefGoogle Scholar
  26. Levy M, Buskila D, Gladman DD, Urowitz MB, Koren G (1991) Pregnancy outcome following first trimester exposure to chloroquine. Am J Perinatol 8: 174–178PubMedCrossRefGoogle Scholar
  27. Meehan RT, Dorsey JK (1987) Pregnancy among patients with systemic lupus erythematosus receiving immunosuppressive therapy. J Rheumatol 14: 252–258PubMedGoogle Scholar
  28. Mirkes PE (1985) Cyclophosphamide teratogenesis: a review. Teratog Carcinog Mutagen 5: 75–88PubMedCrossRefGoogle Scholar
  29. Mogadam M, Dobbins WO, Korelitz BI, Ahmed SW (1981) Pregnancy in inflammatory bowel disease: effect of sulphasalazine and corticosteroids on fetal outcome. Gastroenterology 80: 72–76PubMedGoogle Scholar
  30. Østensen M, Hartmann H, Salvesen K (2000) Low dose weekly methotrexate in early pregnancy: a case series and review of the literature. J Rheumatol 27: 1872–1875PubMedGoogle Scholar
  31. Parke AL (1988) Antimalarial drugs, systemic lupus erythematosus and pregnancy. J Rheumatol 15: 607–610PubMedGoogle Scholar
  32. Parke AL, West B (1996) Hy doxy chloroquine in pregnant patients with systemic lupus erythematosus. J Rheumatol 23: 1715–1718PubMedGoogle Scholar
  33. Park-Wyllie L, Mazzotta P, Pastuszak A, Moretti ME, Beique L, Hunnisett L, Friesen MH, Jacobson S, Kasapinovic S, Chang D, Diav-Citrin O, Chitayat D, Nulman I, Einarson TR, Koren G (2000) Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 62: 385–392PubMedCrossRefGoogle Scholar
  34. Petri M (1998) Pregnancy and SLE. Baillieres Clin Rheumatol 12: 449–476PubMedCrossRefGoogle Scholar
  35. Phillips-Howard PA, Wood D (1996) The safety of antimalarial drugs in pregnancy. Drug Saf 14: 131–145PubMedCrossRefGoogle Scholar
  36. Pilarski LM, Yacyshyn BR, Lazarovits AI (1994) Analysis of peripheral blood lymphocyte populations and immune function from children exposed to cyclosporine or to azathioprine in utero. Transplantation 57: 133–144PubMedCrossRefGoogle Scholar
  37. Pinsky L, DiGeorge AM (1965) Cleft palate in the mouse: a teratogenic index of glucocorticoid potency. Science 147: 402–403PubMedCrossRefGoogle Scholar
  38. Ramsey-Goldman R, Mientus JM, Kutzer JE, Mulvihill JJ, Medsger TA (1993) Pregnancy outcome in women with systemic lupus erythematosus treated with immunosuppressive drugs. J Rheumatol 20: 1152–1157PubMedGoogle Scholar
  39. Registration Committee of the European Dialysis and Transplant Association (1980) Successful pregnancies in women treated by dialysis and kidney transplantation. Br J Obstet Gynaecol 87: 839–845CrossRefGoogle Scholar
  40. Reinisch JM, Simon NG (1978) Prenatal exposure to prednisone in humans and animals retards intrauterine growth. Science 202: 436–438PubMedCrossRefGoogle Scholar
  41. Schleuning M, Clemm C (1987) Chromosomal aberrations in a newborn whose mother received cytotoxic treatment during pregnancy. N Engl J Med 317: 1666–1667PubMedGoogle Scholar
  42. Scott JR (1977) Fetal growth retardation associated with maternal administration of immunosuppressives. Am J Obstet Gynecol 128: 668–676PubMedGoogle Scholar
  43. Shaheen FAM, Al-Sulaiman MH, Al-Khader AA (1993) Long-term nephrotoxicity after exposure to cyclosporine in utero. Transplantation 56: 224–225PubMedCrossRefGoogle Scholar
  44. Stanley CW, Gottlieb R, Zager R, Eisenberg J, Richmond R, Moritz MJ, Armenti VT (1999) Developmental well-being in offspring of women receiving post-renal transplant. Transplant Proc 31: 241–242PubMedCrossRefGoogle Scholar
  45. Williamson RA, Karp LE (1981) Azathioprine teratogenicity: review of the literature and case report. Obstet Gynecol 58: 247–250PubMedGoogle Scholar
  46. Willoughby CP, Truelove SC (1980) Ulcerative colitis and pregnancy. Gut 21: 469–474PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 2003

Authors and Affiliations

  • Monika Østensen
    • 1
  1. 1.Department of Rheumatology and Clinical Immunology/AllergologyUniversity HospitalBerneSwitzerland

Personalised recommendations